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PPARγ playsacentralroleintheformationoffat.RegulationofPPARγ activitydependsonnumerousfactorsrangingfromdietary
ligandstonuclearhormonecoactivatorsandcorepressorstooxygen-sensingmechanisms.Inaddition,theinterplayofPPARγ with
other nuclear hormone receptors has implications for the balance between adipogenesis and osteogenesis in mesenchymal stem
cells of the bone marrow stroma. This review will explore a range of factors inﬂuencing PPARγ activity and how these interactions
may aﬀect osteogenesis.
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INTRODUCTION
This special issue focuses on the latest ﬁndings relating to
the role of PPARs in bone metabolism. This review uses the
broader scope of the nuclear hormone receptor superfamily
to assess the relationship between adipogenesis and osteoge-
nesis, both in vitro and in vivo, and their underlying regula-
tory mechanisms. While PPARγ takes center stage, the vita-
min D3, estrogen, LXR (liver X receptor), and related recep-
tors are used as examples to explore the potential impact of
coactivators and corepressors on bone marrow-derived mes-
enchymalstemcell(MSC)diﬀerentiation.Theroleofdietary
and endogenous ligands, such as genistein, long chain fatty
acids, and resveratrol, are evaluated in the context of nuclear
receptor regulation of bone physiology and pathology.
Bone marrow stroma MSCs give rise to a number of cell
types, including osteoblasts and adipocytes [1, 2]. Bone for-
mation is regulated by Runx2/Cbfa 1, a member of the runt
homology domain transcription factor family [3–6] while fat
formation depends on the peroxisome proliferator-activated
receptor gamma (PPARγ)[ 7–9]. A number of studies sug-
gest that bone formation is related inversely to adipocyte for-
mation in the marrow cavity [2, 10]. In vitro studies using
bonemarrow-derivedMSCsﬁndthatinductionofadipocyte
diﬀerentiation inhibits osteoblastic bone formation [2, 10].
Likewise, agents inducing osteoblast diﬀerentiation inhibit
adipogenesis [11]. These ﬁndings are consistent with the re-
sults of Akune et al [12] demonstrating that haploinsuﬃ-
ciency of PPARγ promotes bone formation.
ThereciprocalrelationshipbetweenPPARγ levelsandos-
teogenesis is particularly evident with increased age [12, 13],
supporting a role for PPARγ in bone development and os-
teoporosis associated with aging. The increasing age of the
population and osteoporosis associated with aging indicates
a need to further explore the regulation of PPARγ with re-
spect to bone formation. The interplay of PPARγ with other
nuclear receptors and the regulation of PPARγ by a range of
cofactors in other tissue types may oﬀer insights into poten-
tial therapeutic targets for regulating bone formation.
PPARγ: CROSSTALK WITH THE CLASSICAL
NUCLEAR RECEPTORS
Originally described as an “orphan” nuclear receptor [14–
17] having no known ligand, the peroxisome proliferator-
activated receptor-γ (PPARγ) has since been identiﬁed as
the target of the widely-used thiazolidinedione (TZD) class
of antidiabetic drugs. Although the thiazolidinediones are
well described as synthetic ligands of PPARγ, the endoge-
nous PPARγ ligand has remained elusive. Long chain fatty
acid derivatives are known to activate PPARγ [18–20], but
the aﬃnity of these natural ligands for PPARγ is well be-
low the aﬃnity of bona ﬁde classical nuclear receptor ligands.
However, there is now an evidence that nitric oxide deriva-
tives of linoleic acid are potent adipogenic agonists at levels
of 133nM, well within the physiological range [21].
In vitro analyses demonstrate that various PPARγ
ligands (rosiglitazone, 9,10 dihydroxyoctadecenoic acid,2 PPAR Research
15-deoxy12,14-PGJ2) not only induce murine bone marrow
stromal cell adipogenesis but also inhibit osteogenesis [22].
However, in vivo models suggest that not all PPARγ ligands
exhibit the same eﬀects [23–25]. For example, long term
treatmentofmicewiththethiazolidinedionetroglitazonein-
creased bone marrow adipocyte content without reducing
bone mass and trabecular volume [23]. In contrast, treat-
ment of mice with rosiglitazaone, a thiazolidinedione with
higher aﬃnity for PPARγ, decreased bone mineral content,
bone formation rates, and trabecular bone volume while in-
creasing adipogenesis [24, 25].
In addition to PPARγ, other nuclear hormone recep-
tors control critical adipogenic and osteogenic steps. Among
these are the estrogen and vitamin D receptors and the inter-
play between PPARγ and these receptors has implications re-
garding the regulation of bone and fat formation in the bone
marrow.
Theeﬀectsofestrogenonboneandadiposetissueforma-
tionhavelongbeenrecognizedinrodentandcanineovariec-
tomy models. In vitro studies using murine bone marrow
MSCs have found that estrogen reciprocally promotes osteo-
genesis while inhibiting adipogenesis [26, 27]. In vitro stud-
ies using murine bone marrow MSCs have found that the
soy phytoestrogen diadzein exhibits a dose dependent bipha-
sic response: low concentrations of diadzein increase osteo-
genesis and decrease adipogenesis while higher doses have
the opposite eﬀect [28]. The reciprocal relationship between
osteogenesis and adipogenesis is attributed to a balance be-
tween diadzein-induced activation of ER (estrogen receptor)
and PPARγ [28] .T h ei m p o r t a n c eo fab a l a n c eb e t w e e nE R
and PPARγ activities is further illustrated by studies indi-
cating that activation of PPARγ with the thiazolidinedione
rosiglitazone in ovariectomized rats is associated with in-
creased bone resorption [29]. Indeed, recent studies show
that a point mutation in the ligand binding domain (exon
6, C161T) of PPARγ is associated with decreased levels of
osteoprotegerin in postmenopausal women [30]. However,
future studies are needed to determine the role of estrogen
receptor and PPARγ “cross-talk” in adipogenesis and osteo-
genesis. Estrogen can exert stimulatory eﬀects on bone for-
mation in the absence of the estrogen receptor alpha (ERα)
[31]. Although estrogen-mediated changes in bone marrow
adipogenesis were not determined in the absence of ERα, the
results suggest that any reciprocal relationship between bone
and fat formation may not require activation of the estrogen
receptor.
CrosstalkbetweenPPARγ andvitaminDreceptor(VDR)
activated pathways also plays a role in the balance between
bone and fat formation. The inbred SAM-P/6 (senescence
accelerated mice-P/6) murine strain provides a model of
accelerated senescence characterized by osteopenia and in-
creased bone marrow fat mass [32]. Recent studies found
that 1.25 (OH)2 vitamin D3 treatment inhibited adipoge-
nesis in the SAM-P/6 mice [33]. This correlated with a
50% reduction in PPARγ mRNA and protein levels as well
as a decrease in Oil Red O positively stained cell num-
bers [33]. Additional studies indicate that 1.25 (OH)2 vita-
min D3 bound VDR blocks adipogenesis by downregulating
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Figure 1: PPARγ and vitamin D receptor interactions with RXRα
may function as a switch between adipogenesis and osteogenesis.
C/EBPβ (CAAT/enhancerbindingprotein),acriticalinducer
of PPARγ transcription early in adipogenesis [34]. However,
ligand-free VDR appears to be necessary for adipogenesis as
“knockdown” of VDR using siRNA prevents the formation
of fat cells [34].
It is tempting to speculate that the inverse relation-
ship between adipogenic and osteogenic diﬀerentiations in
the bone marrow stroma may involve competition between
PPARγ and other nuclear receptors such as the vitamin D
receptor for their common obligate heterodimeric partner,
RXRα (retinoid X receptor) [35] (see Figure 1). In this role,
RXRα is well positioned to regulate the transcriptional ac-
tivity of its binding partners. PPARγ activity is regulated by
PPARγ ligandsaswellastheRXRαligand,9-cis-retinoicacid,
even in the absence of PPARγ ligand binding [36]. Indeed,
adipogenesisisinhibitedinthepresenceof9-cis-retinoicacid
in the murine TMS-14 stromal cell line [37]. Inhibition of
adipogenesis is accompanied by a decrease in PPARγ pro-
tein levels and suggests a decrease in PPARγ transcriptional
activity [37]. Conversely, VDR activity is not aﬀected by 9-
cis-retinoic acid binding to RXRα alone [38]. However, 1.25
(OH)2 D3-bound VDR enhances heterodimerization with
RXRα, resulting in increased VDR activity [38]. The variable
response of PPARγ and VDR to RXRα ligand binding is con-
sistentwiththeideathatRXRαheterodimerizationmayserve
as a dynamic switch in the “decision” to undergo adipogene-
sis or osteogenesis.
PPARγ AND LXR: A CONNECTION BETWEEN LIPID
METABOLISM AND BONE FORMATION
T h el i v e rXr e c e p t o rs u b f a m i l yo fn u c l e a rr e c e p t o r s ,L X R α
and LXRβ, are pivotal in the conversion of cholesterol to
bile acids. While the LXR gene was originally identiﬁed as an
“orphan receptor” based on its heterodimerization with the
9-cis retinoic acid receptor RXR, subsequent studies identi-
ﬁed cholesterol metabolites as endogenous LXR ligands [39].Z. Elizabeth Floyd et al 3
LXR proteins are abundant in adipocytes and recent stud-
ies suggest cross-talk between PPARγ and the LXRs dur-
ing adipogenesis [40–43]. Although the eﬀect of LXR ago-
nists on adipogenesis is unclear [41, 44], several studies in
murine 3T3-L1 cells link LXR to adipogenesis [41–44]. Ho-
mozygous LXRα/β−/− mice have smaller adipose tissue de-
pots compared to their wild type littermates, suggesting that
LXR regulates lipid storage [42, 43]. This eﬀect is attributed
to LXRβ sinceadipose tissueis decreasedin LXRβ−/− but not
LXRα−/− mice [43]. There is evidence that LXR activates the
PPARγ promoter and enhances adipogenesis in 3T3-L1 cells
[44] while other studies indicate that the LXR promoter in
adipocytes is regulated by PPARγ [42]. These ﬁndings sug-
gest that PPARγ and the LXR proteins positively interact in
the formation of adipocytes. However, LXR ligands, such as
theoxysterols20Sand22Rhydroxycholesterol,inhibitadipo-
genesisinducedbythePPARγ ligandtroglitazone[45].These
studies did not determine if the eﬀects of the oxysterols in
adipogenesis were LXR-mediated, leaving open the possibil-
ity that the eﬀects are LXR-independent. It would be inter-
esting to examine the eﬀects of the LXR ligands on adipose
tissue and PPARγ activity in the LXRα−/−β−/− mouse model.
The interplay of LXR and PPARγ in bone formation
is relatively unexplored. While inhibiting adipogenesis, the
oxysterols 20S and 22R hydroxycholesterol enhance osteoge-
nesis [45, 46]. However, inhibition of cholesterol synthesis
andpresumably20Sand22Rhydroxycholesterolbythestatin
compoundsalsoenhancesboneformation[47],andsuggests
decreases in LXR ligands that are associated with osteogene-
sis. At present, these contradictions are diﬃcult to reconcile
and future studies examining the relationship between LXR
(ligandedorunliganded)andPPARγ inadipogenesisandos-
teogenesisshouldprovideimportantinsightsintothesecom-
plex interactions.
PPARγ AND THE NUCLEAR RECEPTOR COREGULATORS:
POTENTIAL ROLES IN BONE FORMATION
The transcriptional activity of the nuclear receptors is also
mediated by interactions of the receptors with a large group
of proteins classiﬁed as coactivators and corepressors of nu-
clear receptor activity. A major category of the coactivators is
the p160 family of proteins that includes the cAMP response
element binding protein (CBP)/p300 and steroid receptor
coactivators (SRC)-1,-2,-3, which recruit histone modiﬁers
to the chromatin structure (reviewed in [48]). A second
category of coactivators includes subunits of the mediator
complex such as the PPAR-binding protein (PBP)/thyroid
hormonereceptor-associatedprotein(TRAP)220/vitaminD
receptor-associatedprotein(DRIP)205[49–51].Thesecoac-
tivators interact with the general transcriptional machinery
to control assembly of the transcription preinitiator com-
plex [49]. TRAP220/DRIP205, originally cloned as a coac-
tivator of the vitamin D receptor [50], interacts directly with
PPARγ [51]. TRAP 220 (−/−) ﬁbroblasts fail to undergo
adipogenesis, indicating that TRAP 220 acts as a PPARγ-
selective coactivator [51]. An additional coactivator, peroxi-
some proliferator-activated receptor gamma interacting pro-
tein (PRIP), serves to link TRAP220/DRIP205 bound PPARγ
to the CBP/p300 coactivator [52]. PRIP (−/−)m o u s eﬁ -
broblasts are also refractory to PPARγ-stimulated adipoge-
nesis [53]. Although these coactivators are relatively unex-
plored in the regulation of osteogenesis, the essential role of
PPARγ in regulating the balance between fat and bone for-
mation strongly implies a role for PPARγ-coactivator inter-
actions in osteogenesis. This possibility is supported by stud-
ies examining the eﬀects of loss of SRC-1 [54–56]. In brown
adipocytes, PPARγ activity is regulated by interaction with
SRC-1 and the PPARγ cofactor 1(PGC-1) [57]. PPARγ tar-
get genes involved in adipogenesis are decreased in SRC-1
and p/CIP (p/300 cointegrator-associated protein) knockout
mice [54]. This is associated with increased metabolic rates
and activity levels, indicating a role for SRC-1/PPARγ inter-
actions in energy balance [54]. Other studies using SRC-1
(−/−) mice have demonstrated that SRC-1 plays a role in
bone responses to estrogen following ovariectomy, particu-
larlyinthemetabolicallyactivetrabecularbone[55,56].Fur-
therstudieswillbeneededtodetermineifSRC-1interactions
with PPARγ inﬂuence responses to estrogen in metabolically
active bone. However, the eﬀects on bone formation associ-
ated with the loss of SRC-1 are expected to be complex given
the general interaction of SRC-1 with nuclear receptors, in-
cluding the estrogen and vitamin D receptors.
A second group of coregulators of PPARγ activity are the
nuclear corepressors, nuclear hormone receptor-corepressor
(N-CoR) [58], and silencing mediator of retinoid and thy-
roid hormone receptor (SMRT) [59]. Repression of nuclear
receptor activity by N-CoR/SMRT involves recruitment of
histone deacetylases to the transcriptional machinery (re-
viewed in [60]). PPARγ and VDR belong to a group of nu-
clear receptors that interact with N-CoR and SMRT in the
absence of ligand [61, 62]. Ligand binding results in disen-
gagement with the corepressors and recruitment of coac-
tivators (reviewed in [60]). Studies using siRNA “knock-
down” of N-CoR and SMRT in murine 3T3-L1 adipocytes
show that these corepressors regulate PPARγ activity dur-
ing adipogenesis [63]. These results are consistent with other
studies indicating that the loss of fat mass associated with
calorie restriction is due to increased interaction of PPARγ
with N-CoR and SMRT [64]. Calorie restriction activates the
histone deacetylase Sirt1, which recruits the N-CoR/SMRT
c o r e p r e s s o rt oP P A R γ leading to inhibition of PPARγ activ-
ityinadipocytes[64].Verylittleisknownabouttheeﬀectsof
calorie restriction on bone formation. However, studies us-
ing resveratrol, a plant polyphenol that, like calorie restric-
tion, activates Sirt1, may oﬀer some insight. Recent stud-
ies in ovariectomized rats show that resveratrol treatment
increases bone mineral density [65]. In addition, resvera-
trol increases the expression of osteocalcin and osteopon-
tin in human bone marrow MSCs [66]. This upregulation
of osteoblast markers is associated with increased responses
to 1, 25 (OH)2 vitamin D3 that are accompanied by in-
creases in expression of the vitamin D receptor [66]. These
results hint at a relationship between repression of PPARγ
activity in adipocytes via interaction with N-CoR/SMRT and
activation of vitamin D receptor responses in osteoblasts.4 PPAR Research
Unraveling a potential relationship between repression of
PPARγ activity via interaction with N-CoR/SMRT and en-
hancement of bone formation may provide new therapeutic
targets in treating osteoporosis in the aging population. An
important area for exploration involves regulation of PPARγ
transcriptional activity via ubiquitin-proteasome-dependent
degradation. The ubiquitin-proteasome system is responsi-
ble for the degradation of short-lived proteins in eukaryotes,
including the nuclear receptors (reviewed in [67]). PPARγ
is targeted for degradation under basal [68] and ligand-
activated conditions [69]. Recent studies show that com-
ponents of the ubiquitin-proteasome system responsible for
targeting substrates for degradation also function as nu-
clear receptor coactivators and corepressors [70–72]. Indeed,
subunits of the N-CoR/SMRT complex are ubiquitin lig-
ases that target substrates for degradation by the 26S pro-
teasome [72]. These components, TBL1/TBLR1 (transducin
β-like 1/transducin β-like 1 related protein), are required for
exchange of corepressors for coactivators upon ligand bind-
ing fora number of nuclearreceptors,including PPARγ [72].
TBL1/TBLR1 act as adaptors for recruiting components of
the ubiquitin-proteasome system to the liganded receptor
[72]. In addition, deletion of TBL1 from mouse embryonic
stem cells precludes the ability of these cells to undergo adi-
pogenesis as judged by staining for neutral lipids and de-
creased gene expression of PPARγ and PPARγ targets such as
adipsin [72]. Given the reciprocal relationship between adi-
pogenesis and osteogenesis, these results suggest a role for
interactions of components ofthe ubiquitin-proteasome sys-
tem with PPARγ (and other nuclear receptors) in determin-
ing the balance between bone and fat formation.
OTHER COREGULATORS OF PPARγ
Additional components of the transcriptional complex also
inﬂuence PPARγ activity and the diﬀerentiation of mes-
enchymal stem cells into either adipocytes or osteoblasts.
New ﬁndings have identiﬁed a coactivator protein, known
as the transcriptional coactivator with PDZ binding motif
(TAZ), that is shared between Runx2 and PPARγ [73, 74].
In murine cell models, the TAZ protein localized to the os-
teocalcin promoter in the presence of bone morphogenic
protein-2 (BMP-2) and coactivated Runx2 and osteogenesis
while directly suppressing PPARγ and adipogenesis [73]. Al-
thoughnotstructurallyrelatedtoβ-catenin,TAZisproposed
to be functionally similar to β-catenin as a regulatory switch
in determining thebalancebetweenosteoblastandadipocyte
development [74]. Wnt signaling stimulates osteogenesis by
induction of osteogenic factors such as Runx2 [75] while
suppressingadipogenesisinmesenchymalstemcells[76,77].
ActivationoftheWntsignalingpathwayleadstoactivationof
β-catenin,whichinterfereswithPPARγ transcriptionalactiv-
ity [78]. Conversely, suppression of Wnt signaling [77]a n d
activation of PPARγ [78] destabilize β-catenin, resulting in
adipogenesis. Future studies will be needed to determine if
β-catenin functions as a direct corepressor of PPARγ activity
in a manner analogous to the TAZ protein. Finally, ligand-
activated PPARγ itself suppresses both the expression and
activityofRunx2[79], adding another regulatory layer to the
balance between bone and fat formation.
Any exploration of PPARγ’s inﬂuence over bone forma-
tion must take into account the eﬀect of oxygen tension on
the development of fat and bone. It is here that the reciprocal
relationship between bone and fat formation seems to disap-
pear. The bone marrow mesenchymal stem cells (bone mar-
r o wM S C )a r en o r m a l l ye x p o s e dt oo x y g e nt e n s i o n sl o w e r
than the atmospheric oxygen tension of 21%. In vitro studies
indicate that low oxygen levels block induction of adipogen-
esis from human and murine MSCs [80]. Human MSCs ac-
cumulate lipid inclusions at low oxygen tensions, but the ap-
pearance of lipids is unaccompanied by expression of PPARγ
or the downstream PPARγ target genes required for adipo-
genesis [81]. Adipogenesis is similarly inhibited under low
oxygen conditions in human adipose-derived mesenchymal
stem cells (ASC) [82]. However, reduced oxygen tension is
also associated with decreased osteogenesis in the human
ASCs [82, 83], suggesting parallel regulation of bone and fat
development under these conditions. While hypoxic condi-
tions (2% oxygen) do not inhibit Runx2 transcriptional ac-
tivity [84], PPARγ transcriptional activity is inhibited un-
der the same conditions [85]. PPARγ inhibition is mediated
by HIF-1α, a hypoxia inducible transcription factor govern-
ing a range of cellular responses to low oxygen levels [85].
HIF-1α mediated repression of PPARγ activity depends on
an HIF-1α regulated transcriptional repressor, DEC1/Stra13
[85]. Interestingly, HIF-1α/DEC1 inhibition of PPARγ under
hypoxic conditions does not involve histone deacetylation,
raising thepossibility thattheclassicalnuclearreceptorcoac-
tivators and corepressors are not required in this process.
CONCLUSIONSAND FUTURE QUESTIONS
These observations suggest that regulation of PPARγ activity
may lie at the heart of determining if bone and fat develop-
ment proceed along parallel or reciprocal directions. Eﬀorts
to understand the regulation of PPARγ transcriptional ac-
tivity have uncovered interplay of PPARγ and other nuclear
hormone receptors that is intricately regulated by a range
of coregulators. The coregulators extend beyond the classi-
cal coactivators and corepressors to include enzymes of the
ubiquitin-proteasome system, components of the Wnt and
BMP-2 signaling pathways, β-catenin and TAZ, and oxygen-
sensing factors such as DEC1/Stra13. As research progresses
in deﬁning the role of PPARγ and other nuclear hormone re-
ceptorsinosteogenesis,someofthequestionstobeanswered
will include the following
(1) Will new insights into MSC adipogenesis and osteo-
genesis be gained as the ligands for “orphan” nuclear
hormone receptors are identiﬁed?
(2) How do additional components of the transcrip-
tionalapparatus,suchashistoneacetylasesandhistone
deacetylases,contributetotheeﬀectsofPPARγ andre-
lated nuclear hormone receptors?
(3) How does ubiquitin-proteasomal targeting of PPARγ
and related nuclear hormone receptors coordinately
regulate MSC adipogenesis and osteogenesis?Z. Elizabeth Floyd et al 5
(4) Will these avenues of investigation have the poten-
tial to yield novel therapeutic targets or identify small
molecules for osteoporosis, osteopenia, and related
bone disorders?
(5) Do adipokines exert either an anabolic or catabolic ef-
fect on osteogenesis?
This ﬁeld of research has advanced rapidly since the discov-
ery of PPARγ o v e rad e c a d ea g o .A sn e wi n v e s t i g a t o r sa r er e -
cruited to this intriguing and clinically relevant ﬁeld, we an-
ticipate that the pace of scientiﬁc progress will continue to
accelerate.
REFERENCES
[1] Beresford JN. Osteogenic stem cells and the stromal system of
bone and marrow. Clinical Orthopaedics and Related Research.
1989;(240):270–280.
[2] Dorheim M-A, Sullivan M, Dandapani V, et al. Osteoblastic
gene expression during adipogenesis in hematopoietic sup-
porting murine bone marrow stromal cells. Journal of Cellular
Physiology. 1993;154(2):317–328.
[3] Banerjee C, McCabe LR, Choi J-Y, et al. Runt homology do-
main proteins in osteoblast diﬀerentiation: AML3/CBFA1 is a
major component of a bone-speciﬁc complex. Journal of Cel-
lular Biochemistry. 1997;66(1):1–8.
[4] Ducy P, Zhang R, Geoﬀroy V, Ridall AL, Karsenty G. Osf2/
Cbfa1: a transcriptional activator of osteoblast diﬀerentiation.
Cell. 1997;89(5):747–754.
[5] Komori T, Yagi H, Nomura S, et al. Targeted disruption of
Cbfa1 results in a complete lack of bone formation owing to
maturational arrest of osteoblasts. Cell. 1997;89(5):755–764.
[6] Otto F, Thornell AP, Crompton T, et al. Cbfa1, a candi-
date gene for cleidocranial dysplasia syndrome, is essential
for osteoblast diﬀerentiation and bone development. Cell.
1997;89(5):765–771.
[7] Tontonoz P, Graves RA, Budavari AI, et al. Adipocyte-speciﬁc
transcription factor ARF6 is a heterodimeric complex of two
nuclear hormone receptors, PPARγ and RXRα. Nucleic Acids
Research. 1994;22(25):5628–5634.
[8] Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM.
mPPARγ2: tissue-speciﬁc regulator of an adipocyte enhancer.
Genes and Development. 1994;8(10):1224–1234.
[9] Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipoge-
nesis in ﬁbroblasts by PPARγ2, a lipid-activated transcription
factor. Cell. 1994;79(7):1147–1156.
[ 1 0 ] B e r e s f o r dJ N ,B e n n e t tJ H ,D e v l i nC ,L e b o yP S ,O w e nM E .E v -
idence for an inverse relationship between the diﬀerentiation
of adipocytic and osteogenic cells in rat marrow stromal cell
cultures. Journal of Cell Science. 1992;102(2):341–351.
[11] Gimble JM, Morgan C, Kelly K, Wu X, Dandapani V, Wang
C-S, Rosen V. Bone morphogenetic proteins inhibit adipocyte
diﬀerentiation by bone marrow stromal cells. Journal of Cellu-
lar Biochemistry. 1995;58(3):393–402.
[12] Akune T, Ohba S, Kamekura S, et al. PPARγ insuﬃciency
enhances osteogenesis through osteoblast formation from
bone marrow progenitors. Journal of Clinical Investigation.
2004;113(6):846–855.
[13] Kawaguchi H, Akune T, Yamaguchi M, et al. Distinct eﬀects of
PPARγ insuﬃciency on bone marrow cells, osteoblasts, and
osteoclastic cells. Journal of Bone and Mineral Metabolism.
2005;23(4):275–279.
[14] Issemann I, Green S. Activation of a member of the steroid
hormone receptor superfamily by peroxisome proliferators.
Nature. 1990;347(6294):645–650.
[15] Dreyer C, Krey G, Keller H, Givel F, Helftenbein G, Wahli W.
Control of the peroxisomal β-oxidation pathway by a novel
family of nuclear hormone receptors. Cell. 1992;68(5):879–
887.
[16] Chen F, Law SW, O’Malley BW. Identiﬁcation of two mPPAR
relatedreceptorsandevidencefortheexistenceofﬁvesubfam-
ily members. Biochemical and Biophysical Research Communi-
cations. 1993;196(2):671–677.
[ 1 7 ]K l i e w e rS A ,F o r m a nB M ,B l u m b e r gB ,e ta l .D i ﬀerential
expression and activation of a family of murine peroxi-
some proliferator-activated receptors. Proceedings of the Na-
tional Academy of Sciences of the United States of America.
1994;91(15):7355–7359.
[18] Brown PJ, Smith-Oliver TA, Charifson PS, et al. Identi-
ﬁcation of peroxisome proliferator-activated receptor lig-
ands from a biased chemical library. Chemistry and Biology.
1997;4(12):909–918.
[19] Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC,
LehmannJM.AprostaglandinJ2 metabolitebindsperoxisome
proliferator-activated receptor γ and promotes adipocyte dif-
ferentiation. Cell. 1995;83(5):813–819.
[20] Kliewer SA, Sundseth SS, Jones SA, et al. Fatty acids and
eicosanoids regulate gene expression through direct interac-
tions with peroxisome proliferator-activated receptors α and
γ. Proceedings of the National Academy of Sciences of the United
States of America. 1997;94(9):4318–4323.
[21] Schopfer FJ, Lin Y, Baker PRS, et al. Nitrolinoleic acid: an en-
dogenous peroxisome proliferator-activated receptor γ ligand.
Proceedings of the National Academy of Sciences of the United
States of America. 2005;102(7):2340–2345.
[22] Lecka-Czernik B, Moerman EJ, Grant DF, Lehmann JM,
Manolagas SC, Jilka RL. Divergent eﬀects of selective perox-
isome proliferator-activated receptor-γ2 ligands on adipocyte
versus osteoblast diﬀerentiation. Endocrinology. 2002;143(6):
2376–2384.
[23] Tornvig L, Mosekilde L, Justesen J, Falk E, Kassem M. Troglita-
zone treatment increases bone marrow adipose tissue volume
but does not aﬀect trabecular bone volume in mice. Calciﬁed
Tissue International. 2001;69(1):46–50.
[24] Ali AA, Weinstein RS, Stewart SA, Parﬁtt AM, Manolagas SC,
JilkaRL.Rosiglitazonecausesbonelossinmicebysuppressing
osteoblast diﬀerentiation and bone formation. Endocrinology.
2005;146(3):1226–1235.
[25] Rzonca SO, Suva LJ, Gaddy D, Montague DC, Lecka-Czernik
B. Bone is a target for the antidiabetic compound rosiglita-
zone. Endocrinology. 2004;145(1):401–406.
[26] Dang ZC, Van Bezooijen RL, Karperien M, Papapoulos SE,
L¨ owik CWGM. Exposure of KS483 cells to estrogen enhances
osteogenesis and inhibits adipogenesis. Journal of Bone and
Mineral Research. 2002;17(3):394–405.
[27] Okazaki R, Inoue D, Shibata M, et al. Estrogen promotes early
osteoblast diﬀerentiation and inhibits adipocyte diﬀerentia-
tion in mouse bone marrow stromal cell lines that express es-
trogenreceptor(ER)α or β. Endocrinology. 2002;143(6):2349–
2356.
[28] Dang Z, L¨ owik CWGM. The balance between concurrent ac-
tivation of ERs and PPARs determines daidzein-induced os-
teogenesis and adipogenesis. Journal of Bone and Mineral Re-
search. 2004;19(5):853–861.
[29] Sottile V, Seuwen K, Kneissel M. Enhanced marrow adipogen-
esisandboneresorptioninestrogen-deprivedratstreatedwith6 PPAR Research
the PPARγ agonist BRL49653 (rosiglitazone). Calciﬁed Tissue
International. 2004;75(4):329–337.
[30] Rhee E-J, Oh K-W, Lee W-Y, et al. The eﬀects of C161 → T
polymorphismsinexon6ofperoxisomeproliferator-activated
receptor-γ gene on bone mineral metabolism and serum os-
teoprotegerin levels in healthy middle-aged women. American
Journal of Obstetrics and Gynecology. 2005;192(4):1087–1093.
[31] Parikka V, Peng Z, Hentunen T, et al. Estrogen responsiveness
ofboneformationinvitroandalteredbonephenotypeinaged
estrogen receptor-α-deﬁcient male and female mice. European
Journal of Endocrinology. 2005;152(2):301–314.
[32] Kajkenova O, Lecka-Czernik B, Gubrij I, et al. Increased adi-
pogenesis and myelopoiesis in the bone marrow of SAMP6,
a murine model of defective osteoblastogenesis and low
turnover osteopenia. Journal of Bone and Mineral Research.
1997;12(11):1772–1779.
[33] Duque G, Macoritto M, Kremer R. 1, 25(OH)2D3 inhibits
bone marrow adipogenesis in senescence accelerated mice
(SAM-P/6) by decreasing the expression of peroxisome
proliferator-activated receptor γ 2( P P A R γ2). Experimental
Gerontology. 2004;39(3):333–338.
[34] Blumberg JM, Tzameli I, Astapova I, Lam FS, Flier JS, Hol-
lenberg AN. Complex role of the vitamin D receptor and its
ligand in adipogenesis in 3T3-L1 cells. Journal of Biological
Chemistry. 2006;281(16):11205–11213.
[35] Mangelsdorf DJ, Evans RM. The RXR heterodimers and or-
phan receptors. Cell. 1995;83(6):841–850.
[36] Schulman IG, Shao G, Heyman RA. Transactivation by
retinoid X receptor-peroxisome proliferator-activated recep-
tor γ (PPARγ) heterodimers: intermolecular synergy requires
only the PPRAγ hormone-dependent activation function.
Molecular and Cellular Biology. 1998;18(6):3483–3494.
[37] Garcia Palacios V, Morita I, Murota S. Expression of adipo-
genesis markers in a murine stromal cell line treated with
15-deoxy Δ12,14-prostaglandin J2, interleukin-11, 9-cis retinoic
acid and vitamin K2. Prostaglandins Leukotrienes and Essential
Fatty Acids. 2001;65(4):215–221.
[38] Lemon BD, Freedman LP. Selective eﬀects of ligands on vita-
min D3 receptor- and retinoid X receptor-mediated gene ac-
tivation in vivo. Molecular and Cellular Biology. 1996;16(3):
1006–1016.
[39] Janowski BA, Willy PJ, Devi TR, Falck JR, Mangelsdorf DJ. An
oxysterol signalling pathway mediated by the nuclear receptor
LXRα. Nature. 1996;383(6602):728–731.
[40] Davies JD, Carpenter KLH, Challis IR, et al. Adipocytic diﬀer-
entiationandliverXreceptorpathwaysregulatetheaccumula-
tionoftriacylglycerolsinhumanvascularsmoothmusclecells.
Journal of Biological Chemistry. 2005;280(5):3911–3919.
[ 4 1 ]H u m m a s t iS ,L a ﬃtte BA, Watson MA, et al. Liver X receptors
are regulators of adipocyte gene expression but not diﬀerenti-
ation: identiﬁcation of apoD as a direct target. Journal of Lipid
Research. 2004;45(4):616–625.
[42] Juvet LK, Andresen SM, Schuster GU, et al. On the role of liver
Xreceptorsinlipidaccumulationinadipocytes. MolecularEn-
docrinology. 2003;17(2):172–182.
[43] Gerin I, Dolinsky VW, Shackman JG, et al. LXRβ is re-
quired for adipocyte growth, glucose homeostasis, and β cell
function.JournalofBiologicalChemistry.2005;280(24):23024–
23031.
[ 4 4 ]S e oJ B ,M o o nH M ,K i mW S ,e ta l .A c t i v a t e dl i v e rXr e c e p t o r s
stimulate adipocyte diﬀerentiation through induction of per-
oxisome proliferator-activated receptor γ expression. Molecu-
lar and Cellular Biology. 2004;24(8):3430–3444.
[45] Kha HT, Basseri B, Shouhed D, et al. Oxysterols regulate dif-
ferentiationofmesenchymalstemcells:pro-boneandanti-fat.
Journal of Bone and Mineral Research. 2004;19(5):830–840.
[46] Shouhed D, Kha HT, Richardson JA, Amantea CM, Hahn TJ,
Parhami F. Osteogenic oxysterols inhibit the adverse eﬀects of
oxidative stress on osteogenic diﬀe r e n t i a t i o no fm a r r o ws t r o -
mal cells. Journal of Cellular Biochemistry. 2005;95(6):1276–
1283.
[47] Mundy G, Garrett R, Harris S, et al. Stimulation of bone
formation in vitro and in rodents by statins. Science. 1999;
286(5446):1946–1949.
[48] Xu J, Li Q. Review of the in vivo functions of the p160
steroid receptor coactivator family. Molecular Endocrinology.
2003;17(9):1681–1692.
[49] Rachez C, Freedman LP. Mediator complexes and transcrip-
tion. Current Opinion in Cell Biology. 2001;13(3):274–280.
[50] FondellJD,GeH,RoederRG.Ligandinductionofatranscrip-
tionally active thyroid hormone receptor coactivator complex.
Proceedings of the National Academy of Sciences of the United
States of America. 1996;93(16):8329–8333.
[51] Ge K, Guermah M, Yuan CX, et al. Transcription coactiva-
torTRAP220isrequiredforPPARγ2-stimulatedadipogenesis.
Nature. 2002;417(6888):563–567.
[52] Qi C, Surapureddi S, Zhu Y-J, et al. Transcriptional coacti-
vator PRIP, the peroxisome proliferator-activated receptor γ
(PPARγ)-interacting protein, is required for PPARγ-mediated
adipogenesis. Journal of Biological Chemistry. 2003;278(28):
25281–25284.
[53] Misra P, Chakrabarti R, Vikramadithyan RK, et al. PAT5A: a
partial agonist of peroxisome proliferator-activated receptor
γ is a potent antidiabetic thiazolidinedione yet weakly adi-
pogenic. Journal of Pharmacology and Experimental Therapeu-
tics. 2003;306(2):763–771.
[54] Wang Z, Qi C, Krones A, et al. Critical roles of the p160 tran-
scriptional coactivators p/CIP and SRC-1 in energy balance.
Cell Metabolism. 2006;3(2):111–122.
[55] M¨ o d d e rU I L ,S a n y a lA ,K e a r n sA E ,e ta l .E ﬀects of loss of
steroid receptor coactivator-1 on the skeletal response to es-
trogen in mice. Endocrinology. 2004;145(2):913–921.
[56] Yamada T, Kawano H, Sekine K, et al. SRC-1 is necessary for
skeletal responses to sex hormones in both males and females.
Journal of Bone and Mineral Research. 2004;19(9):1452–1461.
[57] Puigserver P, Adelmant G, Wu Z, et al. Activation of PPARγ
coactivator-1 through transcription factor docking. Science.
1999;286(5443):1368–1371.
[58] Chen JD, Evans RM. A transcriptional co-repressor that inter-
acts with nuclear hormone receptors. Nature. 1995;377(6548):
454–457.
[59] Horlein AJ, Naar AM, Heinzel T, et al. Ligand-independent re-
pression by the thyroid hormone receptor mediated by a nu-
clear receptor co-repressor. Nature. 1995;377(6548):397–404.
[60] Privalsky ML. The role of corepressors in transcriptional reg-
ulation by nuclear hormone receptors. Annual Review of Phys-
iology. 2004;66:315–360.
[61] Dowell P, Ishmael JE, Avram D, Peterson VJ, Nevrivy DJ, Leid
M. Identiﬁcation of nuclear receptor corepressor as a per-
oxisome proliferator-activated receptor α interacting protein.
Journal of Biological Chemistry. 1999;274(22):15901–15907.
[62] Dwivedi PP, Muscat GEO, Bailey PJ, Omdahl JL, May BK. Re-
pression of basal transcription by vitamin D receptor: evi-
dence for interaction of unliganded vitamin D receptor with
two receptor interaction domains in RIP13Δ1. Journal of
Molecular Endocrinology. 1998;20(3):327–335.Z. Elizabeth Floyd et al 7
[63] Yu C, Markan K, Temple KA, Deplewski D, Brady MJ, Cohen
RN. The nuclear receptor corepressors NCoR and SMRT de-
c r e a s ep e r o x i s o m ep r o l i f e r a t o r - a c t i v a t e dr e c e p t o rγ transcrip-
tional activity and repress 3T3-L1 adipogenesis. Journal of Bi-
ological Chemistry. 2005;280(14):13600–13605.
[64] Picard F, Kurtev M, Chung N, et al. Sirt1 promotes fat mo-
bilization in white adipocytes by repressing PPAR-γ. Nature.
2004;429(6993):771–776.
[65] Liu ZP, Li WX, Yu B, et al. Eﬀects of trans-resveratrol
from Polygonum cuspidatum on bone loss using the ovariec-
tomized rat model. Journal of Medicinal Food. 2005;8(1):14–
19.
[66] Boissy P, Andersen TL, Abdallah BM, Kassem M, Plesner T,
Delaiss´ e J-M. Resveratrol inhibits myeloma cell growth, pre-
vents osteoclast formation, and promotes osteoblast diﬀeren-
tiation. Cancer Research. 2005;65(21):9943–9952.
[67] Nawaz Z, O’Malley BW. Urban renewal in the nucleus: is
protein turnover by proteasomes absolutely required for nu-
clear receptor-regulated transcription? Molecular Endocrinol-
ogy. 2004;18(3):493–499.
[68] Floyd ZE, Stephens JM. Interferon-γ-mediated activation and
ubiquitin-proteasome- dependent degradation of PPARγ in
adipocytes. Journal of Biological Chemistry. 2002;277(6):4062–
4068.
[69] Hauser S, Adelmant G, Sarraf P, Wright HM, Mueller E,
Spiegelman BM. Degradation of the peroxisome proliferator-
activated receptor γ is linked to ligand-dependent activation.
Journal of Biological Chemistry. 2000;275(24):18527–18533.
[70] Nawaz Z, Lonard DM, Smith CL, et al. The Angelman
syndrome-associated protein, E6-AP, is a coactivator for the
nuclear hormone receptor superfamily. Molecular and Cellular
Biology. 1999;19(2):1182–1189.
[71] Verma S, Ismail A, Gao X, et al. The ubiquitin-conjugating en-
zyme UBCH7 acts as a coactivator for steroid hormone recep-
tors. Molecular and Cellular Biology. 2004;24(9):8716–8726.
[72] Perissi V, Aggarwal A, Glass CK, Rose DW, Rosenfeld MG. A
corepressor/coactivator exchange complex required for tran-
scriptional activation by nuclear Receptors and other regu-
lated transcription factors. Cell. 2004;116(4):511–526.
[73] Hong JH, Hwang ES, McManus MT, et al. TAZ, a transcrip-
tional modulator of mesenchymal stem cell diﬀerentiation.
Science. 2005;309(5737):1074–1078.
[74] Hong JH, YaﬀeM B .T A Z :aβ-catenin-like molecule that regu-
lates mesenchymal stem cell diﬀerentiation. Cell Cycle. 2006;5:
176–179.
[75] Bennett CN, Longo KA, Wright WS, et al. Regulation of os-
teoblastogenesis and bone mass by Wnt10b. Proceedings of the
National Academy of Sciences of the United States of America.
2005;102(9):3324–3329.
[76] Bennett CN, Ross SE, Longo KA, et al. Regulation of Wnt
signaling during adipogenesis. Journal of Biological Chemistry.
2002;277:30998–31004.
[77] RossSE,HematiN,LongoKA,etal.Inhibitionofadipogenesis
by Wnt signaling. Science. 2000;289(5481):950–953.
[78] Liu J, Farmer SR. Regulating the balance between perox-
isome proliferator-activated receptor γ and β-catenin sig-
naling during adipogenesis: a glycogen synthase kinase 3β
phosphorylation-defective mutant of β-catenin inhibits ex-
pression of a subset of adipogenic genes. Journal of Biological
Chemistry. 2004;279(43):45020–45027.
[79] Jeon MJ, Kim JA, Kwon SH, et al. Activation of peroxisome
proliferator-activated receptor-γ inhibits the Runx2-mediated
transcriptionofosteocalcininosteoblasts.JournalofBiological
Chemistry. 2003;278(26):23270–23277.
[80] Zhou S, Lechpammer S, Greenberger JS, Glowacki J. Hypoxia
inhibition of adipocytogenesis in human bone marrow stro-
mal cells requires transforming growth factor-β/Smad3 sig-
naling. Journal of Biological Chemistry. 2005;280(24):22688–
22696.
[81] Fink T, Abildtrup L, Fogd K, et al. Induction of adipocyte-
like phenotype in human mesenchymal stem cells by hypoxia.
Stem Cells. 2004;22(7):1346–1355.
[82] LeeJ-H,KempDM.Humanadipose-derivedstemcellsdisplay
myogenic potential and perturbed function in hypoxic condi-
tions. Biochemical and Biophysical Research Communications.
2006;341(3):882–888.
[83] MalladiP,XuY,ChiouM,GiacciaAJ,LongakerMT.Theeﬀect
of reduced oxygen tension on chondrogenesis and osteogene-
sis in adipose-derived mesenchymal cells. American Journal of
Physiology - Cell Physiology. 2006;290(4):1139–1146.
[84] Salim A, Nacamuli RP, Morgan EF, Giaccia AJ, Longaker MT.
Transient changes in oxygen tension inhibit osteogenic diﬀer-
entiation and Runx2 expression in osteoblasts. Journal of Bio-
logical Chemistry. 2004;279(38):40007–40016.
[85] Yun Z, Maecker HL, Johnson RS, Giaccia AJ. Inhibition
of PPARγ2 gene expression by the HIF-1-regulated gene
DEC1/Stra13: a mechanism for regulation of adipogenesis by
hypoxia. Developmental Cell. 2002;2:331–341.